SPDR® S&P Biotech ETF (XBI)

83.57
Delayed Data
As of Sep 17
 -0.29 / -0.35%
Today’s Change
64.38
Today|||52-Week Range
97.60
+16.47%
Year-to-Date

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

No recent news for SPDR® S&P Biotech ETF.

Performance

1 month+1.21% 3 years+9.08%
3 months-2.25% 5 years+9.84%
1 year-11.19% Since inception+13.01%
Data through 09/18/2019

Quote Details

Previous close$83.86
Open day’s range82.51 – 83.94
Net asset value (NAV)83.55 (09/17/2019)
Daily volume2,817,000
Average volume (3 months)4,251,750
Data as of 8:00pm ET, 09/17/2019

Peer Comparisonvs. Health ETFs

 XBICategory
Performance 5-yr return+9.84%+9.15%
Expense Gross exp ratio0.35%1.24%
Risk 5 year sharpe ratio0.400.46
Net assets$3.9B$3.0B
Average market cap$3.4B$35.5B
Average P/E--23.4
Dividend / Share--0.26%

Competitors

FHLC Fidelity® MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...
IHI iShares U.S. Medical Devices ETF

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
GHDX Genomic Health Inc2.22%
NVTA Invitae Corp1.87%
AMGN Amgen1.76%
NBIX Neurocrine Biosciences Inc1.76%
ALNY Alnylam Pharmaceuticals Inc1.71%
ARWR Arrowhead Pharmaceuticals Inc1.70%
MDCO Medicines Co1.69%
PTLA Portola Pharmaceuticals Inc1.67%
ACAD ACADIA Pharmaceuticals Inc1.67%
FGEN FibroGen Inc1.63%